PMC10294262_01
Timeline illustrating schedule of treatment and dosing with T-VEC.
cde530851_f01.jpg
PMC10294262_01_cde530851_f01.jpg
F1
The patient began intralesional T-VEC injections on September 23rd, 2020 (timeline shown in Fig. 1) and has continued to respond to treatment through her last follow-up visit on September 21st, 2022.
Clinical regression of CSCC in renal transplant patient after intralesional injection of T-VEC. a CSCC lesion on May 19th, 2021, before intratumoral injection of 1 mL T-VEC. b June 30th, 2021, 6 weeks after intratumoral T-VEC injection.
cde530851_f02.jpg
PMC10294262_01_cde530851_f02.jpg
F2
Complete regressions on some lesions were observed within 6 weeks of intralesional T-VEC injections (Fig. 2).
Histopathologic imaging of CSCC tumor following intralesional administration of T-VEC (hematoxylin-eosin, original magnification, x10).
cde530851_f03.jpg
PMC10294262_01_cde530851_f03.jpg
F3
Pathology from the resections showed no residual tumor and marked lymphocytic inflammation (Fig. 3).